An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 11, 1999, Pages 1289-1291

  Haslam, Neil ^a   Standen, Graham R ^b   Probert, Christopher S ^b  

^a GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Factor V Leiden; Inflammatory bowel disease; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5; HEPARIN; HETERODUPLEX; ORAL CONTRACEPTIVE AGENT;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DEVICE; ENTERITIS; FEMALE; GENE FREQUENCY; GENE MUTATION; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; INHERITANCE; LEIDEN MUTATION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; THROMBOEMBOLISM; ULCERATIVE COLITIS;

EID: 0032732001     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199911000-00018     Document Type: Article

References (16)

1. Pounder RE. The pathogenesis of Crohn's Disease. J Gastroenterol 1994; 29:1 - 5.
2. Wakefield AJ, Sawyer AM, Hudson M, Dhillon AP, Pounder RE. Smoking, the oral contraceptive pill and Crohn's disease. Dig Dis Sci 1991; 36:1147 - 1150.
3. Lesko SM, Kaufman DW, Rosenburg L, Helmrich SP, Miller DR, Stolley PD, Shapiro S. Evidence for an increased risk of Crohn's Disease in oral contraceptive users. Gastroenterology 1985; 89:1046 - 1049.
4. Thornton JR, Emmett PM, Heaton KW. Smoking, sugar and inflammatory bowel disease. Br Mad J 1985; 290:1786 - 1787.
5. Benini C, Nilsson A. Smoking habits in patients with inflammatory bowel disease: a case-control study. Scand J Gastroenterol 1984; 19:824 - 830.
6. Logan RFA, Kay CR. Oral contraception, smoking and inflammatory bowel disease - findings in the Royal College of General Practitioners oral contraceptive study. Int J Epidemiol 1989; 18:105 - 107.
7. Gaffney PR, Doyle CT, Gaffney A, Hogan J, Hayes DP, Annis P. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995; 90:220 - 223.
8. Levine JB, Lukawski-Trubish D. Extra-intestinal considerations in IBD. Gastroenterology Clinics of North America 1995; 24:633 - 646.
9. Hillarp A, Dahlback B, Zoller B. Activated protein C resistance: from phenotype to genotype and clinical practice. Blood Reviews 1995; 9:201 -212.
10. Bowen DJ, Standen GR, Granville S, Bowley S, Wood NAP, Bidwell J. Genetic diagnosis of factor 5 Leiden using heteroduplex technology. Thromb Haemost 1997; 77:119 - 122.
11. Levine A, Lahav J, Zahavi I, Raz A, Dinari G. Activated protein C resistance in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1998; 26:172 - 174.
12. Heneghan MA, Cleary B, Murray M, O'Gorman TA, McCarthy CF. Activated protein C resistance, thrombophilia and inflammatory bowel disease. Dig Dis Sci 1998; 43:1356 - 1361.
13. Morse C, Standen G, Specificity if clotting methods or factor V Leiden. Br J Haematol 1996; 95:432.
14. Jackson LM, O'Gorman PJ, O'Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. O. J Mod 1997; 90:183 - 188.
15. Liebman HA, Kashami N, Sutherland D, McGehee W, Kam L. The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. Gastroenterol 1998; 115:830 - 834.
16. Canchis PW, Bhan AK, Landau SB, Yang L, Balk SP, Blumberg RS. Tissue distribution of the non-polymorphic major histocompatability complex class I-like molecule, CD1d. Immunology 1993; 80:1 - 5.